Quick Answer
Black Diamond Therapeutics, Inc. reported R&D Expense of $33.56 million for fiscal year 2025.
Black Diamond Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.56M | -34.6% |
| 2024 | $51.31M | -13.5% |
| 2023 | $59.35M | -7.9% |
| 2022 | $64.44M | -33.5% |
| 2021 | $96.83M | +100.9% |
| 2020 | $48.21M | +121.6% |
| 2019 | $21.75M | +213.0% |
| 2018 | $6.95M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.44M | -42.4% | -20.2% |
| June 30, 2025 | $9.32M | -25.8% | -11.3% |
| March 31, 2025 | $10.51M | -22.4% | -18.6% |
| September 30, 2024 | $12.91M | -20.1% | +2.9% |
| June 30, 2024 | $12.56M | -4.5% | -7.3% |
| March 31, 2024 | $13.54M | -8.2% | -16.2% |
| September 30, 2023 | $16.15M | +1.9% | +22.8% |
| June 30, 2023 | $13.15M | -18.8% | -10.8% |
- Black Diamond Therapeutics, Inc. showed a decrease of -34.6% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Black Diamond Therapeutics, Inc.’s r&d expense has grown by 382.8% (from $6.95 million to $33.56 million).
- The most recent figure is from Black Diamond Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: